The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
